SCHEMBL4155826

SCHEMBL4155826

NC(=O)c1ccc2scnc2c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
KDM4E B2RXH2 1/20 0.53
HKDC1 Q2TB90 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
NAMPT P43490 1/20 0.51
HSD11B1 P28845 1/20 0.48
RIPK2 O43353 4/20 0.46
LCK P06239 4/20 0.46
KDR P35968 4/20 0.46
TGFBR1 P36897 4/20 0.46
CRBN Q96SW2 5/20 0.45
DDB1 Q16531 3/20 0.43
CLK1 P49759 1/20 0.43
CLK2 P49760 1/20 0.43
CLK3 P49761 1/20 0.43
ESR1 P03372 1/20 0.43
FASN P49327 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6384354 0.98 NPC1 (0.51) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL162869 0.86 NPC1 (0.72) NPC1RAB9AKDM4EHKDC1TDP1
Hydrochloric Acid SCHEMBL6381967 0.84 NPC1 (0.70) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL30917341 0.84 NPC1 (0.74) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL261022 0.84 NPC1 (0.74) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL5222099 0.83 AURKA (0.55) RIPK2LCKKDRTGFBR1CLK2
SCHEMBL17679198 0.82 NPC1 (0.53) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL27609657 0.82 NPC1 (0.72) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL8861663 0.82 NPC1 (0.53) NPC1RAB9AKDM4EHKDC1TDP1
SCHEMBL27609695 0.82 NPC1 (0.72) NPC1RAB9AKDM4EHKDC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118076602-A Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses 嘉兴优博生物技术有限公司 2024-05-24 CN claimed
CN-116848107-A Compounds and their use as PDE4 activators 米罗尼德有限公司 2023-10-03 CN claimed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US claimed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP claimed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US claimed
WO-2024215917-A1 MITHRAMYCIN (MTM) 2' OXIMES UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2024-10-17 WO disclosed
EP-4387449-A1 METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS & COMPOUNDS THEREFOR Syngenta Crop Protection AG (CH) 2024-06-26 EP disclosed
CN-118076602-A Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses 嘉兴优博生物技术有限公司 2024-05-24 CN disclosed
US-11840530-B2 Selective EP4 receptor antagonistic substance for treatment of cancer ASKAT INC. (JP) 2023-12-12 US disclosed
CN-116848107-A Compounds and their use as PDE4 activators 米罗尼德有限公司 2023-10-03 CN disclosed
WO-2023021020-A1 METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS & COMPOUNDS THEREFOR SYNGENTA CROP PROTECTION AG (CH) 2023-02-23 WO disclosed
US-20220073510-A1 SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER ASKAT INC. (JP) 2022-03-10 US disclosed
US-20140329799-A1 AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS MERCK SHARP & DOHME LLC 2014-11-06 US disclosed
EP-2773207-A1 AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2014-09-10 EP disclosed
WO-2013066729-A1 AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-05-10 WO disclosed
WO-2013066729-A1 AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-05-10 WO disclosed
EP-1543000-A1 INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF Memory Pharmaceuticals Corporation (US) 2005-06-22 EP disclosed
WO-2004029050-A1 INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF MEMORY PHARMACEUTICALS CORPORATION (US) 2004-04-08 WO disclosed
CN-1039415-C Heterocyclic compounds ZENECA LTD (GB) 1998-08-05 CN disclosed
CN-1094400-A Heterogeneous ring compound ZENECA LTD (GB) 1994-11-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073510-A1 SELECTIVE EP4 RECEPTOR ANTAGONISTIC SUBSTANCE FOR TREATMENT OF CANCER PTGER4, PTGER1, PTGER2 NPC1 3051/4885RAB9A 3669/4885KDM4E 2401/4885
US-11840530-B2 Selective EP4 receptor antagonistic substance for treatment of cancer PTGER4, PTGER1, PTGER2 NPC1 3051/4885RAB9A 3669/4885KDM4E 2401/4885
US-20140329799-A1 AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS IRAK4, IRAK1, IRAK2 NPC1 4464/4885RAB9A 1966/4885KDM4E 260/4885
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 NPC1 1371/4885RAB9A 2021/4885KDM4E 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.